Academic Support at Leeds Metropolitan Library

Leeds Metropolitan’s Library Academic Support Stream is made up of Academic Librarians and Information Services Librarians who provide academic support to the university’s six faculties. The team use innovative methods of working together to engage students and enhance their experience. The team only formed a year ago so this is a good time to reflect on our success so far. The library service at Leeds Met is continually developing and offers new challenges and opportunities for staff providing library academic support. Innovation has even become part of our new name – ‘Libraries and Learning Innovation’. We still offer all the traditions types of library academic support, but there is an increasing emphasis on finding innovative ways of supporting students and publicising what we can offer. This year the Library Academic Support Stream won a University Attitude Character and Talents Award for Future Focus

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors

BACKGROUND: We conducted a phase I, multicenter, open-label, dose-finding, and expansion study to determine the safety and preliminary efficacy of eprenetapopt (APR-246) combined with pembrolizumab in patients with advanced/metastatic solid tumors (ClinicalTrials.gov NCT04383938). PATIENTS AND METHODS: For dose-finding, requirements were non-central nervous system primary solid tumor, intolerant to/progressed after ≥1 line of treatment, and eligible for pembrolizumab; for expansion: (i) gastric/gastroesophageal junction tumor, intolerant to/progressed after first-line treatment, and no prior anti-programmed cell death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy; (ii) bladder/urothelial tumor, intolerant to/progressed after first-line cisplatin-based chemotherapy, and no prior anti-PD-1/PD-L1 therapy; (iii) non-small-cell lung cancer (NSCLC) with previous anti-PD-1/PD-L1 therapy. Patients received eprenetapopt 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle. Primary endpoints were dose-limiting toxicity (DLT), adverse events (AEs), and recommended phase II dose (RP2D) of eprenetapopt. RESULTS: Forty patients were enrolled (median age 66 years; range 27-85) and 37 received eprenetapopt plus pembrolizumab. No DLTs were reported and the RP2D for eprenetapopt in combination was 4.5 g/day IV on days 1-4. The most common eprenetapopt-related AEs were dizziness (35.1%), nausea (32.4%), and vomiting (29.7%). AEs leading to eprenetapopt discontinuation occurred in 2/37 patients (5.4%). In efficacy-assessable patients (n = 29), one achieved complete response (urothelial cancer), two achieved partial responses (NSCLC, urothelial cancer), and six patients had stable disease. CONCLUSIONS: The eprenetapopt plus pembrolizumab combination was well tolerated with an acceptable safety profile and showed clinical activity in patients with solid tumors

The Influence of Peers Social Structure in Healthcare Social Networking Websites

Although the demand for online patients to look for online health information is in high, few of them seems to demonstrate effective use of the health Social Network Sites (SNSs) (Fox and Jones 2009). Exploring the design features that can motivate individuals to actively participate in the health SNSs is crucial to develop platforms that can support sustainable online social structures (Butler 2001). This study seeks to investigate the influence of the peers structure capacity as an important feature of health SNSs on two individuals’ behaviors, effective SNSs use and willingness to share Personal Health Information (PHI). Accordingly, our goals in this paper are in twofold: First, identifying the psychological influence of the SNSs structure that helps individuals find others who have similar medical conditions and concerns (i.e. shape their peer group), and second, examining the impact of these psychological factors on effective SNSs use and willingness to disclose PHI

Distributed energy storage system

An energy storage system reaction cell configured for distribution throughout a transport system. The length of the reaction cell is substantially greater than its width and is looped throughout the transport system in a serpentine configuration. A membrane within the reaction cell has a length substantially equal to the length of the reaction cell such that surface area of the membrane is maximized relative to volume of the reaction cell to increase electrical power provided to an electrical load of the transport system

Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

A phase I trial (NCT03447314; 204686) evaluated the safety and efficacy of GSK1795091, a Toll-like receptor 4 (TLR4) agonist, in combination with immunotherapy (GSK3174998 [anti-OX40 monoclonal antibody], GSK3359609 [anti-ICOS monoclonal antibody], or pembrolizumab) in patients with solid tumors. The primary endpoint was safety; other endpoints included efficacy, pharmacokinetics, and pharmacodynamics (PD). Manufacturing of GSK1795091 formulation was modified during the trial to streamline production and administration, resulting in reduced PD (cytokine) activity. Fifty-four patients received GSK1795091 with a combination partner; 32 received only the modified GSK1795091 formulation, 15 received only the original formulation, and seven switched mid-study from the original to the modified formulation. Despite the modified formulation demonstrating higher systemic GSK1795091 exposure compared with the original formulation, the transient, dose-dependent elevations in cytokine and chemokine concentrations were no longer observed (e.g., IP-10, IL10, IL1-RA). Most patients (51/54; 94%) experienced ≥1 treatment-emergent adverse event (TEAE) during the study. Safety profiles were similar between formulations, but a higher incidence of TEAEs associated with immune responses (chills, fatigue, pyrexia, nausea, and vomiting) were observed with the original formulation. No conclusions can be made regarding GSK1795091 anti-tumor activity due to the limited data collected. Manufacturing changes were hypothesized to have caused the change in biological activity in this study. Structural characterization revealed GSK1795091 aggregate size in the modified formulation to be twice that in the original formulation, suggesting a negative correlation between GSK1795091 aggregate size and PD activity. This may have important clinical implications for future development of structurally similar compounds

The Case for Sustainable Concrete Waste Management in Qatar

The construction industry is a major generator of waste. There are many challenges associated with implementing sustainable methods to manage construction waste. While the construction industry in the State of Qatar has been adopting plenty of progressive practices, waste management, especially of concrete waste, has not advanced notably. In addition to the limited supply of limestone suitable for use as natural aggregate for concrete production in Qatar, the ability to recycle and reuse concrete waste is critical to reducing environmental impacts to meet national, regional and global environmental goals. Therefore, this research aims to identify the current status of concrete waste management practices in construction projects in Qatar exemplified by a local case-study project. Concrete waste was particularly monitored over the span of the construction stage of a large research and development facility in Qatar, benchmarking trends and practices on a certified “green” building. In response, this study addresses key challenges to concrete waste recycling and reuse to then recommend opportunities of advancements in local concrete waste management and reuse